Currently Viewing:
ACC 2017
Dr Rob Nolan Discusses Behavioral Foundations of eCounseling Programs
June 10, 2017
Dr Rob Nolan Explains Behavioral Principles Behind eCounseling Hypertension Program
May 15, 2017
Dr Seth J. Baum on the Patient's Role in Getting PCSK9 Inhibitors Approved by Payers
May 10, 2017
Dr William Borden Discusses MACRA Requirements From a Cardiologist's Perspective
May 08, 2017
Dr Janet Wright on Cardiologists' Role in Public Health and Prevention Efforts
April 15, 2017
Dr Rob Nolan on the Future Directions of eCounseling Research
April 14, 2017
Dr Seth J. Baum Discusses Payers' Reluctance to Approve Coverage of PCSK9 Inhibitors
April 07, 2017
Dr Janet Wright Discusses How Million Hearts Will Leverage Partnerships for Success
April 06, 2017
Dr Robert P. Giugliano Discusses the Significance of the FOURIER and EBBINGHAUS Trials
April 06, 2017
Currently Reading
Dr Seth J. Baum on the Patient's Role in Getting PCSK9 Inhibitors Approved by Payers
March 20, 2017
Charting the Path to Health Equity: Steps for Providers
March 20, 2017
Dr Janet Wright Outlines Goals and Roadblocks of Million Hearts Initiative
March 20, 2017
Dr William Borden: Advice for Cardiologists on Adjusting to MACRA
March 19, 2017
Dr Rob Nolan Discusses Findings From REACH Hypertension eCounseling Trial
March 19, 2017
Can SGLT2 Inhibitors Prevent Heart Failure in a Broad Population?
March 19, 2017
Data Show It's Hard to Fill PCSK9 Prescriptions, Confirming Cardiologists' Complaints
March 19, 2017
Dr Robert P. Giugliano on the Results of the EBBINGHAUS Evolocumab Cognitive Study
March 18, 2017
Low-Dose Xarelto Beats Aspirin for Long-Term Prevention of Life-Threatening Blood Clots
March 18, 2017
Bringing MACRA to Cardiologists, Ready or Not
March 17, 2017

Dr Seth J. Baum on the Patient's Role in Getting PCSK9 Inhibitors Approved by Payers

It remains unclear why insurers approve some patients for PCSK9 inhibitors while denying others with similar clinical characteristics, according to Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, president of the American Society for Preventive Cardiology, who presented an abstract on the subject at the American College of Cardiology 66th Scientific Session.


It remains unclear why insurers approve some patients for PCSK9 inhibitors while denying others with similar clinical characteristics, according to Seth J, Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, president of the American Society for Preventive Cardiology, who presented an abstract on the subject at the American College of Cardiology 66th Scientific Session. However, Baum said there are steps clinicians, and more importantly patients, can take to improve the chances of payer approval.

What characteristics make patients more likely to be approved by payers for PCSK9 inhibitors?

It would be great to really know what characteristics make patients more likely to be approved or denied for PCSK9 inhibitors. We had an abstract at this meeting showing that we can’t really tell, so we looked at approval and denial rates for patients on high-intensity statins, on high-intensity statins and ezetimibe, on dual antiplatelet therapy, which is really synonymous for ASCVD [atherosclerotic cardiovascular disease], and there was no significant difference between approval and denial for those categories.

So at this point, it’s looking pretty haphazard, almost capricious, how approval and denials are actually being processed through the payers.

Is there anything patients and clinicians can do to make PCSK9 inhibitor approval more likely?

Patients and clinicians can make things easier or better. I would say the most important thing to do is for patients to become involved. Patients absolutely have the loudest voice.

When a patient contacts an insurance company and says, “Hey, I was prescribed this medication and denied this medication, yet it’s on your formulary and my doctor believes that I need it,” the clock actually starts at that point and the patient’s grievance is recorded. When a doctor calls, it doesn’t happen, so we have to do that in parallel: the patient has to be involved, the doctor has to be involved.

From the doctor’s standpoint, the important thing to do is to document, document, document, just make sure you fill out the prior authorization perfectly. I’d like to suggest that in addition to the prior authorization required by the company, use the simplified prior authorization that we’re going to have online through Clinical Cardiology, and when enough people do that I think we’re going to show the insurance companies that they need to utilize this simplified prior authorization.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!